111 research outputs found
The role of CD180 in hematological malignancies and inflammatory disorders.
Toll-like receptors play a significant role in the innate immune system and are also involved in the pathophysiology of many different diseases. Over the past 35 years, there have been a growing number of publications exploring the role of the orphan toll-like receptor, CD180. We therefore set out to provide a narrative review of the current evidence surrounding CD180 in both health and disease. We first explore the evidence surrounding the role of CD180 in physiology including its expression, function and signaling in antigen presenting cells (APCs) (dendritic cells, monocytes, and B cells). We particularly focus on the role of CD180 as a modulator of other TLRs including TLR2, TLR4, and TLR9. We then discuss the role of CD180 in inflammatory and autoimmune diseases, as well as in hematological malignancies of B cell origin, including chronic lymphocytic leukemia (CLL). Based on this evidence we produce a current model for CD180 in disease and explore the potential role for CD180 as both a prognostic biomarker and therapeutic target. Throughout, we highlight specific areas of research which should be addressed to further the understanding of CD180 biology and the translational potential of research into CD180 in various diseases
Morphological and histochemical analyses of two human T-cell subpopulations bearing receptors for IgM or IgG.
Irf4 is a positional and functional candidate gene for the control of serum IgM levels in the mouse
Natural IgM are involved in numerous immunological functions but the genetic factors that control the homeostasis of its
secretion and upholding remain unknown. Prompted by the finding that C57BL/6 mice had significantly lower serum levels of
IgM when compared with BALB/c mice, we performed a genome-wide screen and found that the level of serum IgM was
controlled by a QTL on chromosome 13 reaching the highest level of association at marker D13Mit266 (LOD score¼3.54).
This locus was named IgMSC1 and covered a region encompassing the interferon-regulatory factor 4 gene (Irf4). The number
of splenic mature B cells in C57BL/6 did not differ from BALB/c mice but we found that low serum levels of IgM in C57BL/6 mice
correlated with lower frequency of IgM-secreting cells in the spleen and in the peritoneal cavity. These results suggested that
C57BL/6 mice have lower efficiency in late B-cell maturation, a process that is highly impaired in Irf4 knockout mice. In fact, we
also found reduced Irf4 gene expression in B cells of C57BL/6 mice. Thus, we propose Irf4 as a candidate for the IgMSC1
locus, which controls IgM homeostatic levels at the level of B-cell terminal differentiation
- …